

# World Journal of *Virology*

*World J Virol* 2014 May 12; 3(2): 11-17





## Editorial Board

2011-2015

The *World Journal of Virology* Editorial Board consists of 341 members, representing a team of worldwide experts in virology. They are from 58 countries, including Argentina (5), Australia (6), Austria (3), Barbados (1), Belgium (2), Brazil (6), Bulgaria (1), Cameroon (1), Canada (11), Chile (1), China (52), Croatia (2), Cuba (1), Czech Republic (1), Denmark (1), Egypt (2), Ethiopia (1), Finland (4), France (11), Germany (12), Ghana (1), Greece (2), Hungary (1), India (11), Indonesia (1), Iran (1), Ireland (3), Israel (5), Italy (24), Japan (13), Kazakhstan (1), Kenya (1), Kosovo (1), Mexico (2), Netherlands (6), New Zealand (1), Nigeria (1), Pakistan (2), Palestine (1), Poland (1), Portugal (1), Romania (1), Russia (2), Saudi Arabia (1), Senegal (1), Singapore (2), Slovakia (1), Slovenia (2), South Africa (3), South Korea (4), Spain (14), Sweden (3), Thailand (8), Tunisia (1), Turkey (4), United Kingdom (7), United States (82), and Uruguay (1).

### EDITOR-IN-CHIEF

Ling Lu, *Kansas*

### GUEST EDITORIAL BOARD MEMBERS

Chi-Ho Chan, *Taichung*  
Shih-Cheng Chang, *Taoyuan*  
Hsin-Wei Chen, *Miaoli County*  
Shun-Hua Chen, *Tainan*  
Steve S Chen, *Taipei*  
Wei-June Chen, *TaoYuan*  
Jiann Ruey Hong, *Tainan*  
Reuben Jih-Ru Hwu, *Hsinchu*  
Cheng-Wen Lin, *Taichung*  
Na-Sheng Lin, *Taipei*  
Tzou-Yien Lin, *Taoyuan*  
Hsin-Fu Liu, *New Taipei*  
Hung-Jen Liu, *Taichung*  
Szecheng J Lo, *Tao Yuan*  
Menghsiao Meng, *Taichung*  
Wen-Ling Shih, *Pingtung*  
Robert YL Wang, *TaoYuan*  
Chang-Jer Wu, *Keelung*  
Chi-Chiang Yang, *Taichung*  
Kung-Chia Young, *Pingtung*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

Angela Gentile, *Buenos Aires*  
Pablo Daniel Ghiringhelli, *Bernal*  
Giselle Paula Martín Ocampos, *La Plata*  
Jorge Victorio Pavan, *Córdoba*

Laura Elena Valinotto, *Buenos Aires*



#### Australia

Shisan Bao, *Sydney*  
Jiezhong Chen, *Wollongong*  
Russell J Diefenbach, *Westmead*  
Ian Maxwell Mackay, *Brisbane*  
David Peter Wilson, *Sydney*  
Kong-Nan Zhao, *Herston*



#### Austria

Adly MM Abd-Alla, *Vienna*  
Sabine Brandt, *Vienna*  
Thomas Lion, *Vienna*



#### Barbados

Alok Kumar, *Bridgetown*



#### Belgium

Jan P Clement, *Leuven*  
Jelle Matthijssens, *Leuven*



#### Brazil

Luciano K de Souza Luna, *Ribeirão Preto*  
Luciane Pinto Gaspar, *Curitiba*  
Thiago Moreno Le Souza, *Rio De Janeiro*  
José P G Leite, *Rio de Janeiro*

Sonia Mara Raboni, *Curitiba*

Livia Melo Villar, *Rio De Janeiro*



#### Bulgaria

Irena Petkova Kostova, *Sofia*



#### Cameroon

Richard Njouom, *Yaounde*



#### Canada

Earl Garnet Brown, *Ottawa*  
Ivan Brukner, *Montreal*  
Max Alexander Chernesky, *Hamilton*  
Alain Houde, *Quebe*  
Peter J Krell, *Guelph*  
Jean F Laliberté, *Vancouver*  
Honglin Luo, *Vancouver*  
Xianzhou Nie, *Fredericton*  
Jean-Pierre Routy, *Montreal*  
Aiming Wang, *Ontario*  
Decheng Yang, *Vancouver*



#### Chile

Marcelo López-Lastra, *Santiago*



#### China

Kun-Long Ben, *Kunming*  
Guang-Wen Cao, *Shanghai*

Paul Kay Sheung Chan, *Hong Kong*  
 Yuan-Ding Chen, *Kunming*  
 An-Chun Cheng, *Ya'an*  
 Shang-Jin Cui, *Harbin*  
 Xiao-Ping Dong, *Beijing*  
 Zai-Feng Fan, *Beijing*  
 Jean-Michel Garcia, *Hong Kong*  
 Xiu-Guo Hua, *Shanghai*  
 Wen-Lin Huang, *Guangdong*  
 Margaret Ip, *Hong Kong*  
 Dao-Hong Jiang, *Wuhan*  
 Jian-Qi Lian, *Xi'an*  
 Xin-Yong Liu, *Jinan*  
 Xiao-Yang Mo, *Changsha*  
 Beatrice Nal, *Hong Kong*  
 Cheng-Feng Qin, *Beijing*  
 Hua-Ji Qiu, *Harbin*  
 Xiao-Feng Ren, *Harbin*  
 Huai-Chang Sun, *Yangzhou*  
 Jian-Wei Wang, *Beijing*  
 Ning Wang, *Beijing*  
 You-Chun Wang, *Beijing*  
 Mary Miu Yee Waye, *Hong Kong*  
 Patrick CY Woo, *Hong Kong*  
 Jian-Qing Wu, *Nanjing*  
 Rui Wu, *Luoyang*  
 Yu-Zhang Wu, *Chongqing*  
 Chuang-Xi Zhang, *Hangzhou*  
 Guo-Zhong Zhang, *Beijing*  
 Chun-Fu Zheng, *Wuhan*



#### **Croatia**

Snjezana Zidovec Lepej, *Zagreb*  
 Pero Lučin, *Rijeka*



#### **Cuba**

Maria G Guzman, *La Habana*



#### **Czech Republic**

Daniel Ruzek, *Ceske Budejovice*



#### **Denmark**

Håvard Jenssen, *Roskilde*



#### **Egypt**

Samia Ahmed Kamal, *Cairo*  
 Abdel-Rahman Zekri, *Cairo*



#### **Ethiopia**

Woldaregay Erku Abegaz, *Addis Ababa*



#### **Finland**

Jussi Hepojoki, *Helsinki*  
 Anne Jääskeläinen, *Helsinki*  
 Irmeli Lautenschlager, *Helsinki*

Antti Vaheri, *Helsinki*



#### **France**

Laurent Belec, *Paris*  
 Christian A Devaux, *Montpellier*  
 Jean Dubuisson, *Lille*  
 Wattel Eric, *Lyon*  
 Duverlie Gilles, *Amiens*  
 Gilles Gosselin, *Montpellier*  
 Bedouelle Hugues, *Paris*  
 Eric J Kremer, *Montpellier*  
 Denis Rasschaert, *Tours*  
 Farzin Roohvand, *Tehran and Paris*  
 Christian Trépo, *Lyon*



#### **Germany**

Gualtiero Alvisi, *Heidelberg*  
 Claus Thomas Bock, *Berlin*  
 Andreas Dotzauer, *Bremen*  
 Ingo Drexler, *Düsseldorf*  
 Christoph Eisenbach, *Heidelberg*  
 Thomas Iftner, *Göttingen*  
 Florian Lang, *TuBingen*  
 Michael Nevels, *Regensburg*  
 Stefan Pöhlmann, *Göttingen*  
 Andreas MH Sauerbrei, *Jena*  
 Jonas Schmidt-Chanasit, *Hamburg*  
 Frank Tacke, *Aachen*



#### **Ghana**

Kwamena W Sagoe, *Accra*



#### **Greece**

Apostolos I Beloukas, *Athens*  
 George V Papatheodoridis, *Athens*



#### **Hungary**

Krisztián Bányai, *Budapest*



#### **India**

Akhil C Banerjee, *New Delhi*  
 Jayta Bhattacharyaan, *Pune*  
 Runu Chakravarty, *Kolkata*  
 Sibnarayan Datta, *Tezpur*  
 Jitendra Kumar, *Punjab*  
 Sunil Kumar Mukherjee, *New Delhi*  
 Ramesh S Paranjape, *Pune*  
 Sharma Pradeep, *Kamal*  
 HK Pradhan, *New Delhi*  
 Shamala D Sekaran, *New Delhi*  
 Rasappa Viswanathan, *Coimbatore*



#### **Indonesia**

Andi Utama, *Tangerang*



#### **Iran**

Seyed M Ghiasi, *Tehran*



#### **Ireland**

Carlo Bidoia, *Dublin*  
 Liam J Fanning, *Cork*  
 Weifeng Shi, *Dublin*



#### **Israel**

Irit Davidson, *Bet Dagan*  
 Yedidya Gafni, *Bet Dagan*  
 Murad Ghanim, *Bet Dagan*  
 Murad Ghanim, *Rehovot*  
 Raz Jelinek, *Beer Sheva*



#### **Italy**

Alberto Alberti, *Sassari*  
 Gualtiero Alvisi, *Padua*  
 Giorgio Barbarini, *Voghera*  
 Massimiliano Berretta, *Aviano*  
 Franco Maria Buonaguro, *Naples*  
 Maria R Capobianchi, *Procida*  
 Arnaldo Caruso, *Brescia*  
 Daniel Oscar Cicero, *Buenos Aires*  
 Marco Ciotti, *Rome*  
 Cristina Costa, *Turin*  
 Piergiuseppe De Berardinis, *Naples*  
 Federico De Marco, *Rome*  
 Massimo EA De Paschale, *Legnano*  
 Maurizia Debiaggi, *Pavia*  
 Paolo Fabris, *Vicenza*  
 Daniele Focosi, *Pisa*  
 Simone Giannecchini, *Florence*  
 Roberto Manfredi, *Bologna*  
 Vito Martella, *Bari*  
 Nicola Principi, *Milan*  
 Giuseppe Portella, *Aichi Prefecture*  
 Giovanni Rezza, *Rome*  
 Diego Ripamonti, *Bergamo*  
 Teresa Antonia Santantonio, *Foggia*



#### **Japan**

Masashi Emoto, *Maebashi*  
 Bin Gotoh, *Otsu*  
 Kazuyoshi Ikuta, *Suita*  
 Hiroki Isomura, *Nagoya*  
 Hideya Kawasaki, *Suita*  
 Eiichi N Kodama, *Sendai*  
 Hiromitsu Moriyama, *Tokyo*  
 Kenji Okuda, *Aichi Prefecture*  
 Ikuo Shoji, *Aichi Prefecture*  
 Nobuhiro Suzuki, *Kurashiki*  
 Takashi Suzuki, *Kurashiki*  
 Akifumi Takaori-Kondo, *Kyoto*  
 Tetsuya Toyoda, *Toyohashi*



#### **Kazakhstan**

Vladimir E Berezin, *Almaty*



**Kenya**

George Gachara Maina, *Nairobi*

**Kosovo**

Lul Raka, *Nairobi*

**Mexico**

Juan Ernesto Ludert, *Mexico City*  
Julio Reyes-Leyva, *Metepc*

**Netherlands**

KS Meriaha Benschop, *Amsterdam*  
Ben Berkhout, *Amsterdam*  
Byron EE Martina, *Rotterdam*  
Willem JG Melchers, *Nijmegen*  
Monique Nijhuis, *Utrecht*  
John W Rossen, *Tilburg*

**New Zealand**

Olga S Garkavenko, *Auckland*

**Nigeria**

Olajide Adewale Owolodun, *Jos*

**Pakistan**

Muhammad Masroor Alam, *Islamabad*  
Muhammad Imran Qadir, *Faisalabad*

**Palestine**

Ahamd Y Amro, *Jerusalem*

**Poland**

Brygida Knysz, *Wroclaw*

**Portugal**

Celso Cunha, *Lisbon*

**Romania**

Anda Baicus, *Bucharest*

**Russia**

Anton Buzdin, *Moscow*  
Elena Vasil'evna Gavrilova, *Novosibirsk*

**Saudi Arabia**

Ahmed Sayed Abdel-Moneim, *Al-Taif*

**Senegal**

Assan Jaye, *Banjul*

**Singapore**

Sophie Bellanger, *Singapore*  
Ding Xiang Liu, *Singapore*

**Slovakia**

Gabriela Bukovska, *Bratislava*

**Slovenia**

Uros Krapez, *Ljubljana*  
Andrej Steyer, *Ljubljana*

**South Africa**

Huub C Gelderblom, *Durban*  
Dirk Stephan, *Stellenbosch*  
Janusz Tadeusz Paweska, *Stellenbosch*

**South Korea**

Sang Hoon Ahn, *Seoul*  
Tae-Jin Choi, *Busan*  
Junsoo Park, *Wonju*  
Sang heui Seo, *Daejeon*

**Spain**

Alfredo Berzal-Herranz, *Granada*  
Rafael Blasco, *Madrid*  
Luis Enjuanes, *Madrid*  
Juan Martínez Hernández, *Madrid*  
Jaime Gómez Laguna, *Córdoba*  
Cecilio Lopez-Galindez, *Madrid*  
F Xavier López-Labrador, *Valencia*  
José A Melero, *Madrid*  
Luis Menéndez-Arias, *Madrid*  
Andrés Moya, *Valencia*  
David Roiz Pereda, *Granada*  
Pilar Perez-Romero, *Sevilla*  
Juan-Carlos Saiz, *Madrid*  
Natalia Soriano-Sarabia, *Madrid*

**Sweden**

Göran P L Bucht, *Umeå*  
Ali Mirazimi, *Stockholm*  
Bo F Oberg, *Huddinge*

**Thailand**

Prasert Auewarakul, *Bangkok*

Parin Chaivisuthangkura, *Bangkok*  
Wasin Charerntantanakul, *Chiang Mai*  
Wansika Kiatpathomchai, *Bangkok*  
Sasisopin Kiertiburanakul, *Bangkok*  
Winyou Mitarnun, *Chiang Mai*  
Yong Poovorawan, *Bangkok*  
Viroj Wiwanitkit, *Bangkok*

**Tunisia**

Olfa Bahri, *Tunis*

**Turkey**

Ömer Coşkun, *Ankara*  
İftihar Koksall, *Trabzon*  
Aykut Ozdarendeli, *Kayseri*  
Ayca Arzu Sayiner, *Izmir*

**United Kingdom**

Shiu-Wan Chan, *Manchester*  
Maurizio Chiriva-Internati, *Nottingham*  
Iain M Morgan, *Glasgow*  
Mark Richard Nelson, *London*  
Adrian William Philbey, *Glasgow*  
James P Stewart, *Liverpool*  
Gavin W G Wilkinson, *Cardiff*

**United States**

Nafees Ahmad, *Tucson*  
Ashok Aiyar, *Los Angeles*  
Judith M Ball, *Texas*  
Igor M Belyakov, *Gaithersburg*  
Lbachir BenMohamed, *Irvine*  
Preeti Bharaj, *Orlando*  
Jay C Brown, *Virginia*  
Victor Ephraim Buckwold, *Walkersville*  
Alexander Bukreyev, *Galveston*  
Joseph John Carter, *Seattle*  
Maria Graciela Castro, *Los Angeles*  
YanPing Chen, *Beltsville*  
Xiaojiang S Chen, *Los Angeles*  
Pawel S Ciborowski, *Omaha*  
Harel Dahari, *Chicago*  
David A Davis, *Omaha*  
Don J Diamond, *Duarte*  
Vincent N Fondong, *Dover*  
Phillip A Furman, *Princeton*  
Shou-Jiang Gao, *San Antonio*  
Kaplan Gerardo, *Bethesda*  
David Richard Gretch, *Seattle*  
Hailong Guo, *Rochester*  
Haitao Guo, *Doylestown*  
Young Shin Hahn, *Charlottesville*  
Amnon Hizi, *Bethesda*  
Kuan-The Jeang, *Bethesda*  
Wei Jiang, *Charleston*  
Xia Jin, *Rochester*  
Clinton Jimmie Jones, *Lincoln*  
Robert Jordan, *Oregon*  
Adriana Elisa Kajon, *Albuquerque*  
Krishna MV Ketha, *Bethesda*  
Paul R Kinchington, *Pittsburgh*  
Prasad S Koka, *San Diego*

Sachin Kumar, *College Park*  
 Majid Laassri, *Rockville*  
 Feng Li, *Brookings*  
 Jin Ling, *corvallis*  
 Ling Lu, *Kansas City*  
 Yuanan Lu, *Honolulu*  
 Paolo Lusso, *Bethesda*  
 Barry Joseph Margulies, *Towson*  
 Michael Raymond McConnell, *San Diego*  
 Ulrich Karl Melcher, *Stillwater*  
 George Miller, *Stillwater*  
 Mansour Mohamadzadeh, *Chicago*  
 Thomas P Monath, *Menlo Park*  
 Jonathan Patrick Moorman, *Johnson City*  
 Egbert Mundt, *Stillwater*  
 Karuppiah Muthumani, *Philadelphia*  
 Eleftherios Mylonakis, *Boston*

Hiroyuki Nakai, *Pittsburgh*  
 Debiprosad Nayak, *Los Angeles*  
 Anthony V Nicola, *Richmond*  
 Shunbin Ning, *Miami*  
 Phillipe N Nyambi, *New York*  
 Krishan K Pandey, *Saint Louis*  
 Virendra N Pandey, *Saint Louis*  
 Eric Murnane Poeschla, *Rochester*  
 Andrew Patrick Rice, *Houston*  
 Jacques Robert, *Rochester*  
 Rachel Lee Roper, *Greenville*  
 Deepak Shukla, *Chicago*  
 Andrey Sorokin, *Milwaukee*  
 Qiyl Tang, *Ponce*  
 Yajarayma J Tang Feldman, *Davis*  
 Ikuo Tsunoda, *Shreveport*  
 Sharof M Tugizov, *San Francisco*

Xiu-Feng Wan, *Mississippi State*  
 Jane Huiru Wang, *Willowbrook*  
 Xiuqing Wang, *Brookings*  
 Xinzheng Yang, *Boston*  
 Zhiping Ye, *Bethesda*  
 Dongwan Yoo, *Urbana*  
 Kyoungjin J Yoon, *Ames*  
 Lijuan Yuan, *Blacksburg*  
 Yan Yuan, *Boston*  
 Hong Zhang, *Rockville*  
 Luwen Zhang, *Lincoln*  
 Zhi-Ming Zheng, *Bethesda*



**Uruguay**

Matias Victoria, *Salto*

**CLINICAL TRIALS  
STUDY**

- 11 Semen lactoferrin promotes CCL20 production by epithelial cells: Involvement in HIV transmission

*Lourenço AG, Komesu MC, Machado AA, Quintana SM, Bourlet T, Pozzetto B, Delézay O*

## Contents

*World Journal of Virology*  
Volume 3 Number 2 May 12, 2014

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** Editorial Board Member of *World Journal of Virology*, Wen-Ling Shih, PhD, Associate Professor, Graduate Institute of Biotechnology, National Pingtung University of Science and Technology 1, Shuefu Rd., Neipu, Pingtung 91201, Taiwan

**AIM AND SCOPE** *World Journal of Virology* (*World J Virol*, *WJV*, online ISSN 2220-3249, DOI: 10.5501) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJV* covers topics concerning arboviral infections, bronchiolitis, central nervous system viral diseases, DNA virus infections, encephalitis, eye infections, fatigue syndrome, hepatitis, meningitis, opportunistic infections, pneumonia, RNA virus infections, sexually transmitted diseases, skin diseases, slow virus diseases, tumor virus infections, viremia, zoonoses, and virology-related traditional medicine, and integrated Chinese and Western medicine. Priority publication will be given to articles concerning diagnosis and treatment of viral diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJV*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING** *World Journal of Virology* is now indexed in PubMed Central, PubMed, and Digital Object Identifier.

**FLYLEAF** I-IV Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Su-Qing Liu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*  
Proofing Editorial Office Director: *Xin-Xia Song*

**NAME OF JOURNAL**  
*World Journal of Virology*

**ISSN**  
ISSN 2220-3249 (online)

**LAUNCH DATE**  
February 12, 2012

**FREQUENCY**  
Quarterly

**EDITOR-IN-CHIEF**  
**Ling Lu, MD, PhD**, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, 3901 Rainbow Blvd, WHE 3020, KS 66160, United States

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director

*World Journal of Virology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: editorialoffice@wjnet.com  
Help Desk: <http://www.wjnet.com/esps/helpdesk.aspx>  
<http://www.wjnet.com>

**PUBLISHER**  
Baishideng Publishing Group Inc  
8226 Regency Drive,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: bpgoffice@wjnet.com  
Help Desk: <http://www.wjnet.com/esps/helpdesk.aspx>  
<http://www.wjnet.com>

**PUBLICATION DATE**  
May 12, 2014

## COPYRIGHT

© 2014 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

## SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

## INSTRUCTIONS TO AUTHORS

Full instructions are available online at [http://www.wjnet.com/2220-3249/g\\_info\\_20100722180909.htm](http://www.wjnet.com/2220-3249/g_info_20100722180909.htm).

## ONLINE SUBMISSION

<http://www.wjnet.com/esps/>

## Semen lactoferrin promotes CCL20 production by epithelial cells: Involvement in HIV transmission

Alan Grupioni Lourenço, Marilena Chinalli Komesu, Alcyone Artioli Machado, Silvana Maria Quintana, Thomas Bourlet, Bruno Pozzetto, Olivier Deléazay

Alan Grupioni Lourenço, Alcyone Artioli Machado, Silvana Maria Quintana, Division of Infectious Diseases, Department of Internal Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, 14049-900 São Paulo, Brazil  
 Alan Grupioni Lourenço, Marilena Chinalli Komesu, Department of Morphology, Stomatology and Physiology, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, 14049-900 São Paulo, Brazil

Alan Grupioni Lourenço, Thomas Bourlet, Bruno Pozzetto, Olivier Deléazay, EA3064, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Faculty of Medicine Jacques Lisfranc, University of Lyon, 42023 Saint-Etienne, France

**Author contributions:** Lourenço AG, Komesu MC, Machado AA, Pozzetto B and Deléazay O conceived the research; Machado AA and Quintana SM recruited the patients and provided the samples; Lourenço AG, Bourlet T and Deléazay O performed the experiments; Lourenço AG, Komesu MC, Quintana SM, Bourlet T and Deléazay O analyzed the data; Lourenço AG, Komesu MC and Pozzetto B wrote the paper.

Supported by The Brazilian Federal Agency CAPES (Coordenação de Aperfeiçoamento de Pessoal de nível Superior) and evaluation of graduate education

Correspondence to: Bruno Pozzetto, MD, PhD, Professor, Director of the Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP) group, EA3064, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Faculty of Medicine Jacques Lisfranc, University of Lyon, 15 Rue Ambroise Paré, 42023 Saint-Etienne, France. [bruno.pozzetto@univ-st-etienne.fr](mailto:bruno.pozzetto@univ-st-etienne.fr)  
 Telephone: +33-4-77828434 Fax: +33-4-77828460

Received: December 31, 2013 Revised: May 4, 2014

Accepted: May 9, 2014

Published online: May 12, 2014

### Abstract

**AIM:** To study the effect of seminal plasma on Chemokine (C-C motif) ligand 20 (CCL20) production by epithelial cells and its relationship with lactoferrin.

**METHODS:** HEC-1A cells, a cell line derived from a monostratified endocervical epithelium, were incubated

with samples of seminal plasma (diluted 1:10 in culture medium) recovered from human immunodeficiency virus (HIV) seronegative (HIV-) or HIV seropositive (HIV+) subjects. Recombinant human interleukin 1 beta (IL-1 $\beta$ ) was used as positive control, and culture medium only as negative control. The measurement of CCL20 production in the supernatants of HEC-1A cells and of lactoferrin in seminal plasma was determined by enzyme-linked immunosorbent assay techniques. A fractionation of seminal plasma proteins was performed by ion exchange chromatography on a pool of seminal plasma specimens from HIV- subjects. Each fraction was tested for its ability to stimulate the production of CCL20 by HEC-1A cells and for its lactoferrin concentration. The HIV viral load in seminal plasma samples from HIV+ patients was measured using the HIV-Monitor kit (Roche Diagnostic Systems, Branchburg, NJ, United States).

**RESULTS:** The positive control IL-1 $\beta$  was responsible for an increase of  $11.36 \pm 3.36$  times in the production of CCL20. Stimulation of HEC-1A cells was performed in 34 seminal plasma samples (22 from HIV+ subjects and 12 from HIV- subjects). The mean production of CCL20 by HEC-1A in presence of seminal plasma from HIV- and HIV+ subjects was respectively  $5.38 \pm 0.91$  and  $7.57 \pm 3.26$  times higher than that obtained with the untreated cells ( $P < 0.05$  between the two groups). Using the same 34 specimens of seminal plasma, no correlation was observed between the concentration of total proteins in seminal plasma and their ability to stimulate the secretion of CCL20 by HEC-1 cells. In contrast, the ability to produce CCL20 by HEC-1A cells correlated to the concentration of lactoferrin in the seminal plasma samples ( $r$  coefficient = 0.56; CI: 0.26-0.76;  $P < 0.001$ ). After fractionation by ion exchange chromatography, the seminal plasma fractions exhibiting the highest concentrations of lactoferrin were responsible for the greatest stimulation of CCL20 production by HEC-1A cells ( $r$  coefficient = 0.89; CI: 0.78-0.95;  $P <$



0.0001).

**CONCLUSION:** Lactoferrin present in seminal plasma correlated with an increased production of CCL20 by HEC-1A cells and therefore could facilitate HIV entry through the genital mucosa.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Human immunodeficiency virus/acquired immunodeficiency syndrome; Sexual transmission; Seminal plasma; CCL20; Lactoferrin; Endocervical epithelial cells

Lourenço AG, Komesu MC, Machado AA, Quintana SM, Bourlet T, Pozzetto B, Deléay O. Semen lactoferrin promotes CCL20 production by epithelial cells: Involvement in HIV transmission. *World J Virol* 2014; 3(2): 11-17 Available from: URL: <http://www.wjgnet.com/2220-3249/full/v3/i2/11.htm> DOI: <http://dx.doi.org/10.5501/wjv.v3.i2.11>

## INTRODUCTION

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) accounts for 60% to 90% of new infections, especially in developing countries. During male-to-female transmission, the virus is typically deposited in the vagina as cell-free or cell associated virions carried by semen<sup>[1]</sup>. In the absence of breaches in the genital mucosa, the epithelium crossing by HIV could occur through the recruitment of immune cells with migratory properties, such as macrophages, lymphocytes or Langerhans cells (LCs), the latter cells being considered as one of the first target for this virus<sup>[2]</sup>. HIV entry may be observed at different levels of the female genital tract including the vagina, the ectocervix and the endocervix. The epithelial architecture is variable in these regions. The epithelium of vagina and ectocervix is composed by multi-layered, pluristratified epithelial cells that do not form a polarized epithelium. In contrast, the epithelium of the endocervix is a single layer of polarized, columnar epithelial cells with tight junctions, dividing the epithelium into apical and basolateral domains<sup>[3]</sup>. These simple mono-layered epithelia provide a lower degree of protection.

The Chemokine (C-C motif) ligand 20 (CCL20) is liberated by epithelial cells from different tissues including skin<sup>[4,5]</sup>, oral mucosa<sup>[6]</sup> and vaginal epithelium<sup>[7]</sup>. CCL20 is an important immune effector molecule that is chemotactic for immature dendritic cells (DCs) and lymphocytes<sup>[8,9]</sup>. DCs also likely contribute to the array of cells potentially involved in HIV entry into the vaginal and ectocervical mucosae. DCs efficiently capture, disseminate, and transmit viruses to mononuclear target cells; however, HIV does not productively infect the DCs themselves<sup>[3]</sup>. CCL20 secretion by human vaginal epithelial cells has been shown to be enhanced in the presence of semen resulting in chemoattraction

of LCs that are permissive to HIV infection<sup>[10]</sup>, but the compound(s) involved in this stimulation is (are) not yet characterized.

This study was performed for analyzing the ability of seminal plasma from HIV seronegative (HIV-) and HIV seropositive (HIV+) subjects to promote the production of CCL20 by monolayers of endocervical epithelium cells (HEC-1A cell line). This secretion correlated to the amount of lactoferrin present in the seminal plasma specimen.

## MATERIALS AND METHODS

### Seminal plasmas samples

Semen samples were collected from 22 HIV+ and 12 HIV- subjects. The patients gave their fully-informed written consent. The study was reviewed and approved by the Ethics Committee of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil (CH-SMRP-USP No. 4926/2009). The inclusion criteria were as follows: being over 18 years old, having never undergone radiotherapy or chemotherapy treatment, and not having used antimicrobials or anti-inflammatory drugs during the last 6 mo. HIV- men were tested for the absence of common sexually transmitted diseases including syphilis, *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection, herpes simplex virus infection and hepatitis B virus infection.


The participants were instructed to auto-perform an aseptic collection of semen by masturbation into a universal collector, with the use of neither lubricants nor water. Within 4 h after ejaculation, the semen specimens were submitted to the following protocol: they were diluted 1:2 in PBS and then centrifuged at 800 g for 30 min. The supernatant constituted the seminal plasma that was stored at -80 °C. The frozen samples were sent to the GIMAP team, Saint Etienne, France, for analysis.

### Cell culture

The HEC-1A cell line was used for mimicking the female genital tract. It was cultured in Dulbecco's minimal essential medium (DMEM-F12 medium, Cambrex BioScience, Verviers, Belgium) to which were added 2% fetal bovine serum (FBS) and 1% solution containing penicillin, streptomycin and amphotericin B (Sigma-Aldrich, St. Louis, MO, United States). The experiments of stimulation were performed on 96-well culture plates (BD Falcon, Franklin Lakes, NJ, United States) seeded with cells cultured for 2 d with a final density of 100000 cells/well.

### Measurement of the secretion of CCL20 by HEC-1A cells

HIV- or HIV+ seminal plasmas diluted 1:10 in culture medium were added to the HEC-1A cells. Recombinant human interleukin 1 beta (IL-1β) (Peprotech, Neuilly-Sur-Seine, France) at the concentration 25 ng/mL was used as positive control, as previously reported<sup>[7,10]</sup>. Culture medium DMEM-F12 served as negative control. After an overnight incubation, the CCL20 production



**Figure 1** The Chemokine (C-C motif) ligand 20 production by HEC-1A cells exposed to seminal plasma specimens from human immunodeficiency virus-seronegative- or human immunodeficiency virus-seropositive+ subjects as expressed by comparison to untreated cells [Chemokine (C-C motif) ligand 20 index]. Interleukin-1 beta (IL-1 $\beta$ ) was used as positive control. <sup>a</sup>*P* < 0.05. SP: Seminal plasma; HIV: Human immunodeficiency virus-seronegative.

was measured in the supernatants of HEC-1A cells by using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, R and D Systems, Abingdon, United Kingdom) as recommended by the manufacturer. Each assay was performed in duplicate. The results were expressed as relative CCL20 index corresponding to the ratio between the amount of CCL20 produced by the specimen and the negative control (culture medium only).

#### **Viral load in seminal plasma**

The HIV-Monitor kit (Roche Diagnostic Systems, Branchburg, NJ, United States) was used to quantify the HIV RNA in seminal plasma samples from HIV+ subjects. The detection lower limit was of 50 copies/mL. The RNA was extracted from the specimens using a modified silica protocol (QIAmp RNA viral kit; Qiagen, Chatsworth, CA, United States).

#### **Measurement of lactoferrin in seminal plasma**

Measurement of lactoferrin in seminal plasma specimens was performed by ELISA technique. A standard curve was prepared by using different concentrations of lactoferrin from human milk (Sigma-Aldrich). Seminal plasma samples (diluted 1:10 in PBS) were distributed into wells at the concentration of 100  $\mu$ L per well and incubated at 37  $^{\circ}$ C for 1 h. Albumin from chicken egg whites (Sigma-Aldrich) was used for blocking. Lactoferrin was detected with rabbit anti-human lactoferrin antibodies (L3262; Sigma-Aldrich) incubated for 1 h at room temperature followed by peroxidase conjugated anti-rabbit antibodies (Sigma-Aldrich). After several washes, o-phenylenediamine was used as substrate and optical densities at 492 nm were measured. Each assay was performed in duplicate.

#### **Measurement of total protein in seminal plasma**

The Bradford technique was used for the measurement of the total protein content<sup>[11]</sup>. Seminal plasma was dilut-

ed 1:75 in PBS and distributed in triplicate in microplate wells under a volume of 150  $\mu$ L per well in addition to the same volume of Bradford reagent (Sigma-Aldrich). Bovine serum albumin was used to perform the standard curve. The reading was performed by spectrophotometry at 590 nm.

#### **Fractionation of seminal plasma by ion exchange chromatography**

Specimens of seminal plasma from HIV- subjects were diluted 1:10 in 50 mmol/L NaCl pH 7.4 (buffer A) and applied onto a column of affinity (Hitrap Q FF, GE Healthcare Life sciences, Velizy-Villacoublay, France) equilibrated at room temperature with the same buffer. A discontinuous gradient was used for the elution of seminal plasma proteins by using six different concentrations (5%, 10%, 20%, 30%, 40%, 50%) of a buffer containing 500 mmol/L NaCl (buffer B). Buffer B was passed through the column at a flow rate of 0.5 mL/min using the HPLC AKTA purifier system (GE Healthcare Life sciences). The successive fractions were tested for their capability to induce the secretion of CCL20 by HEC-1A cells as well as for lactoferrin and total protein content as described above.

#### **Statistical analysis**

The data expressed in experimental units are presented as mean  $\pm$  SD. Statistical analyses were performed using the GraphPad Prism software (San Diego, CA, United States). The Mann-Whitney test was used to compare two means. Correlations were analyzed using the Spearman's *r* test. *P* values < 0.05 were considered as statistically significant.


## **RESULTS**

#### **Seminal plasma promotes the induction of secretion of CCL20 by HEC-1A cells**

The secretion of CCL20 was measured by ELISA in the supernatants of HEC-1A cells incubated for 17 h with culture medium DMEM-F12 only (negative control), IL-1 $\beta$  (25 ng/mL, positive control) or each of 34 seminal plasma specimens (22 from HIV+ subjects and 12 from HIV- subjects) diluted 1:10 in DMEM-F12. The CCL20 stimulation was expressed in number of times its production increased in comparison to untreated cells (CCL20 index). IL-1 $\beta$  used as positive control was responsible for an increase of  $11.36 \pm 3.36$  times in the production of CCL20. The mean production of CCL20 by HEC-1A in presence of seminal plasma from HIV- and HIV+ subjects was increased by respectively  $5.38 \pm 0.91$  and  $7.57 \pm 3.26$  times with comparison to untreated cells (negative control). The difference between the two groups was statistically significant (*P* < 0.05 by Mann-Whitney test) (Figure 1).

#### **CCL20 production by HEC-1A cells correlated with lactoferrin in seminal plasma**

Using the same 34 specimens of seminal plasma (12



**Figure 2** Correlation between total protein (A) or lactoferrin concentrations (B) and Chemokine (C-C motif) ligand 20 production by HEC-1A cells stimulated with seminal plasma. Seminal plasma from HIV-negative (open triangles) or HIV-positive subjects (closed circles). Lf: Lactoferrin; HIV: Human immunodeficiency virus-seronegative. CCL20: Chemokine (C-C motif) ligand 20.

from HIV- and 22 from HIV+ subjects), no correlation was observed between the concentration of total proteins in seminal plasma and their ability to stimulate the secretion of CCL20 by HEC-1 cells (Figure 2A). In contrast, the ability to produce CCL20 by HEC-1A cells positively correlated to the concentration of lactoferrin in the seminal plasma samples ( $r$  coefficient = 0.56; CI: 0.26-0.76;  $P < 0.001$  by the Spearman's  $r$  test) (Figure 2B).

### Seminal plasma fractions with the highest concentrations of lactoferrin were responsible for the greatest stimulation of CCL20 by HEC-1A cells

In order to verify whether lactoferrin present in seminal plasma was responsible for the production of CCL20 by HEC-1A cells, the proteins from a pool of seminal plasma specimens from 12 HIV- subjects were fractionated by ion exchange chromatography. Each fraction was then tested for its ability to stimulate the production of CCL20 and for its concentration of lactoferrin and total proteins (Figure 3).

As shown in Figure 3B, the amount of CCL20 produced by HEC-1A cells was closely related to the concentration of lactoferrin present in the plasma fraction ( $r = 0.8942$ , CI: 0.7773-0.9514,  $P < 0.0001$  by the Spearman's  $r$  test). Fractions with the greatest concentration of lactoferrin (fractions 1, 3-5, 7-9, 10-13 in Figure 3B) corresponded to those exhibiting the highest capacity for inducing the production of CCL20 by HEC-1A cells.

### Correlation between viral load in seminal plasma from HIV+ subjects and its ability to stimulate the production of CCL20 by HEC-1A cells

From the 22 seminal plasma specimens from subjects tested seropositive for HIV, the 5 samples exhibiting a detectable viral load ( $> 50$  copies/mL) increased the production of CCL20 by a factor of  $10.3 \pm 4.2$  times as compared to the negative control whereas the 17 samples with undetectable viral load ( $< 50$  copies/mL) stimulated the production of CCL20 by a factor of  $6.7 \pm 2.6$  times

with reference to the negative control. A trend was observed between the 2 groups but the difference was not statistically significant due to the small size of effectives (Figure 4).


## DISCUSSION

Heterosexual route is the most common way for HIV transmission resulting in a significant increase of HIV-infected women in recent years<sup>[12,13]</sup>. Women are more susceptible to HIV transmission, notably because of the large size of genital mucosa that is exposed to semen and also because semen contains higher concentrations of virus than vaginal fluid<sup>[14]</sup>.

Seminal plasma confers a survival advantage to spermatozooids within the relative hostile environment of the female genital tract<sup>[15]</sup>. However, more recent studies have shown that seminal plasma is able to provide to vaginal mucosa a set of signaling molecules that are capable of interacting with epithelial cells of the female reproductive tract, these interactions triggering molecular and cellular changes that resemble an inflammatory response<sup>[16]</sup>.

Signaling molecules present in seminal plasma may increase the secretion of chemokines and cause vascular changes that lead to the recruitment and activation of macrophages, granulocytes and DCs<sup>[17]</sup> including LCs<sup>[10]</sup>. LCs present in the vaginal mucosa are known as "Trojan horse" that facilitate the passage of HIV through the vaginal mucosa and present them to the CD4+ cells<sup>[18]</sup>. CCL20 is the main chemokine involved in the recruitment of LCs and its production by epithelial cells could be related to an increased risk of HIV infection. In this way, Li *et al*<sup>[19]</sup> demonstrated that the reduction of CCL20 secretion by epithelial cells treated with glycerol monolaurate, a vaginal microbicide, prevented the mucosal transmission of Simian Immunodeficiency Virus. These data are an additional argument for the determining role of CCL20 in the contamination process by HIV.

In this study, we found that seminal plasma was able



**Figure 3** Fractionation by ion exchange chromatography of pooled seminal plasma specimens from 12 human immunodeficiency virus-seronegative subjects. A: Total protein (upper curve) and lactoferrin (lower curve) concentrations, expressed in  $\mu\text{g/mL}$ , in each fraction; B: Correlation between the CCL20 index after stimulation of HEC-1A cells by each fraction (closed squares) and its concentration in lactoferrin expressed in  $\mu\text{g/mL}$  (closed circles).


to stimulate the production of CCL20 by HEC-1A, with a statistically significant advantage for that originated from HIV+ patients as compared to HIV- subjects. These results confirm those previously published by our team<sup>[10]</sup> that showed a higher increase in the production of CCL20 by the SiHa cell line derived from vaginal epithelium when stimulated with seminal plasma from HIV+ subjects, however without statistical significance. Sharkey *et al.*<sup>[17]</sup> also showed that human seminal plasma is capable of interacting with cervical and vaginal tissues for inducing the production of proinflammatory cytokines.

Cremel *et al.*<sup>[7]</sup> demonstrated that vaginal epithelial cells increased the secretion of CCL20 in response to stimulation by proinflammatory cytokine IL-1 $\beta$ . The present study shows that seminal plasma from HIV+ and HIV-

subjects produces similar effects on the cells lining the endocervical monostratified (HEC-1A), suggesting that seminal plasma contains components able to generate a response, even if not specific, in the female genital mucosa, mediated by CCL20 secretion.

One of the potential candidates that could stimulate CCL20 secretion by female genital epithelial cells is lactoferrin, a globular glycoprotein of the transferrin family with a molecular mass of 80 kDa and present in large amounts in various secretions. Lactoferrin is considered as an important element of nonspecific humoral immunity and was shown to exhibit a protective effect, particularly against HIV because of its interference with the viral gp 120 and Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin receptor





**Figure 4** The Chemokine (C-C motif) ligand 20 production by HEC-1A cells treated with seminal plasma from human immunodeficiency virus-positive subjects with either detectable viral load > 50 copies/mL or undetectable viral load (< 50 copies/mL). CCL20: Chemokine (C-C motif) ligand 20; VL: Viral load.

receptor<sup>[20,21]</sup>. In contrast, other studies have reported that some peptides from the cleavage of this protein by elastase or proteinase type III enzymes exhibit a strong pro-inflammatory activity in different mucosae<sup>[22,23]</sup>. In this study, we found a positive correlation between the concentration of lactoferrin in seminal plasma and the production of CCL20 stimulated by HEC-1A, even if it cannot be excluded that an additional factor could contribute to this activation. Another finding of our study that suggests the participation of lactoferrin or its cleavage products as activating factors of increased secretion of CCL20 by genital mucosal cells is the result obtained after chromatography fractionation performed on a pool of seminal plasma samples from HIV- subjects (the volume of seminal plasma was not enough to perform the same experiments with seminal plasma samples from HIV+ subjects). Indeed, the fractions that were the most efficient for CCL20 secretion stimulation were those containing the highest concentration of lactoferrin. The fact that the lactoferrin activity was distributed in discontinuous pattern along the chromatogram (Figure 3B) could be explained by the tetrameric conformation of the protein that can correspond to associations of different molecular masses, and also by the contribution of degradation products of lactoferrin after enzymatic digestion, which were shown to exhibit a strong pro-inflammatory effect<sup>[22,23]</sup>.

Interestingly, as shown in Figure 4 for the subgroup of HIV+ subjects, the specimens exhibiting high viral loads were shown to stimulate more efficiently the production of CCL20 (although the difference did not reach statistical significance due to the small size of effectives); this finding is an additional evidence for the existence of a correlation between the HIV load of seminal fractions and their ability to promote CCL20 stimulation. Viral shedding in seminal plasma was recently shown to be closely related to the presence of high levels of pro-inflammatory cytokines, including granulocyte colony stimulating factor, tumor necrosis factor- $\alpha$ , interfer-

on- $\gamma$  and IL-10<sup>[24]</sup>. In the light of the above discussion regarding lactoferrin, it can be hypothesized that the amount of pro-inflammatory components derived from this protein may be higher in HIV+ than in HIV- subjects, and notably in those with high seminal HIV load.

All these data argue in favor of a significant role of lactoferrin or its degradation products on CCL20 secretion by female genital mucosa. Despite the need of complementary studies for confirming these findings, our results are indicative of the role of some of these proteins in HIV transmission through the female epithelium tract and suggest that they must be taken into consideration for the prevention of HIV heterosexual contamination process. From a clinical point of view, it would be useful to identify the molecules implicated in this facilitation in order to develop intra-vaginal products capable of neutralizing their activity.

## COMMENTS

### Background

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) accounts for 60% to 90% of new infections, especially in developing countries. During male-to-female transmission, in the absence of breaches in the genital mucosa, the epithelium crossing by HIV could occur through the recruitment of immune cells with migratory properties, such as macrophages, lymphocytes or Langerhans cells.

### Research frontiers

The Chemokine (C-C motif) ligand 20 (CCL20) secretion by human vaginal epithelial cells has been shown to be enhanced in the presence of semen resulting in chemoattraction of Langerhans cells that are permissive to HIV infection, but the compound(s) involved in this stimulation is (are) not yet characterized.

### Innovations and breakthroughs

In the present study, seminal plasma was shown to promote the induction of secretion of CCL20 by monolayers of endocervical epithelium cells (HEC-1A cell line). The effect was significantly higher with seminal plasma from HIV seropositive than HIV seronegative subjects. CCL20 production by HEC-1A cells correlated with the concentration of lactoferrin in seminal plasma. After fractionation of seminal plasma, those with the highest concentrations of lactoferrin were responsible for the greatest stimulation of CCL20 by HEC-1A cells. In conclusion, lactoferrin present in seminal plasma correlated with an increased production of CCL20 by HEC-1A cells and therefore could facilitate HIV entry through the genital mucosa.

### Applications

Lactoferrin itself or, more likely, some of its degradation products could facilitate HIV entry through the recruitment of immune cells. It would be interesting to characterize precisely the molecules involved in this phenomenon in order to evaluate if they may constitute a target for antiviral protection.

### Terminology

The CCL20 is an important immune effector molecule that is able to attract immature immune cells. Lactoferrin is a globular glycoprotein of the transferrin family that is present in large amounts in various secretions, including seminal plasma; it is considered as an important element of nonspecific humoral immunity.

### Peer review

The current article described the seminal plasma/ lactoferrin affects the CCL20 production by HEC-1 cells. It is an interesting and important topic.

## REFERENCES

- 1 Doncel GF, Joseph T, Thurman AR. Role of semen in HIV-1 transmission: inhibitor or facilitator? *Am J Reprod Immunol* 2011; 65: 292-301 [PMID: 21087339 DOI: 10.1111/j.1600-0897.2010.00931]
- 2 Lore K, Larsson M. The role of dendritic cells in the patho-



- genesis of HIV-1 infection. *APMIS* 2003; **111**: 776-788 [PMID: 12974779 DOI: 10.1034/j.1600-0463.2003.11107809.x]
- 3 **Shen R**, Richter HE, Smith PD. Early HIV-1 target cells in human vaginal and ectocervical mucosa. *Am J Reprod Immunol* 2011; **65**: 261-267 [PMID: 21118402 DOI: 10.1111/j.1600-0897.2010.00939.x]
- 4 **Sperling T**, Oldak M, Walch-Rückheim B, Wickenhauser C, Doorbar J, Pfister H, Malejczyk M, Majewski S, Keates AC, Smola S. Human papillomavirus type 8 interferes with a novel C/EBP $\beta$ -mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration. *PLoS Pathog* 2012; **8**: e1002833 [PMID: 22911498 DOI: 10.1371/journal.ppat.1002833]
- 5 **Dieu-Nosjean MC**, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Caux C. Macrophage inflammatory protein 3 $\alpha$  is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. *J Exp Med* 2000; **192**: 705-718 [PMID: 10974036 DOI: 10.1084/jem.192.5.705]
- 6 **Abiko Y**, Nishimura M, Kusano K, Nakashima K, Okumura K, Arakawa T, Takuma T, Mizoguchi I, Kaku T. Expression of MIP-3 $\alpha$ /CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. *Arch Oral Biol* 2003; **48**: 171-175 [PMID: 12642237 DOI: 10.1016/S0003-9969(02)00167-X]
- 7 **Cremel M**, Berlier W, Hamzeh H, Cognasse F, Lawrence P, Genin C, Bernengo JC, Lambert C, Dieu-Nosjean MC, Delézay O. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. *J Leukoc Biol* 2005; **78**: 158-166 [PMID: 15831560 DOI: 10.1189/jlb.0305147]
- 8 **Blengio F**, Raggi F, Pierobon D, Cappello P, Eva A, Giovarelli M, Varesio L, Bosco MC. The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. *Immunobiology* 2013; **218**: 76-89 [PMID: 22465745 DOI: 10.1016/j.imbio.2012.02.002]
- 9 **Schutysse E**, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. *Cytokine Growth Factor Rev* 2003; **14**: 409-426 [PMID: 12948524 DOI: 10.1016/S1359-6101(03)00049-2]
- 10 **Berlier W**, Cremel M, Hamzeh H, Lévy R, Lucht F, Bourlet T, Pozzetto B, Delézay O. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. *Hum Reprod* 2006; **21**: 1135-1142 [PMID: 16531471 DOI: 10.1093/humrep/dei496]
- 11 **Bradford MM**. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248-254 [PMID: 942051]
- 12 **Cohn SE**, Clark RA. Sexually transmitted diseases, HIV, and AIDS in women. *Med Clin North Am* 2003; **87**: 971-995 [PMID: 14621327]
- 13 **Higgins JA**, Hoffman S, Dworkin SL. Rethinking gender, heterosexual men, and women's vulnerability to HIV/AIDS. *Am J Public Health* 2010; **100**: 435-445 [PMID: 20075321]
- 14 **Yi TJ**, Shannon B, Prodder J, McKinnon L, Kaul R. Genital immunology and HIV susceptibility in young women. *Am J Reprod Immunol* 2013; **69** Suppl 1: 74-79 [PMID: 23157424]
- 15 **Denison FC**, Grant VE, Calder AA, Kelly RW. Seminal plasma components stimulate interleukin-8 and interleukin-10 release. *Mol Hum Reprod* 1999; **5**: 220-226 [PMID: 10333355 DOI: 10.1093/molehr/5.3.220]
- 16 **Robertson SA**. Seminal plasma and male factor signalling in the female reproductive tract. *Cell Tissue Res* 2005; **322**: 43-52 [PMID: 15909166 DOI: 10.1007/s00441-005-1127-3]
- 17 **Sharkey DJ**, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. *Mol Hum Reprod* 2007; **13**: 491-501 [PMID: 17483528 DOI: 10.1093/molehr/gam028]
- 18 **Piguet V**, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. *J Invest Dermatol* 2002; **119**: 365-369 [PMID: 12190858 DOI: 10.1046/j.1523-1747.2002.01840.x]
- 19 **Li Q**, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT. Glycerol monolaurate prevents mucosal SIV transmission. *Nature* 2009; **458**: 1034-1038 [PMID: 19262509 DOI: 10.1038/nature07831]
- 20 **Groot F**, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, van Kooyk Y, de Jong EC, Berkhout B. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. *J Virol* 2005; **79**: 3009-3015 [PMID: 15709021 DOI: 10.1128/JVI.79.5.3009-3015.2005]
- 21 **Kazmi SH**, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. *Clin Vaccine Immunol* 2006; **13**: 1111-1118 [PMID: 16928883 DOI: 10.1128/CDLI.00426-05]
- 22 **Komine K**, Komine Y, Kuroishi T, Kobayashi J, Obara Y, Kumagai K. Small molecule lactoferrin with an inflammatory effect but no apparent antibacterial activity in mastitic mammary gland secretion. *J Vet Med Sci* 2005; **67**: 667-677 [PMID: 16082114 DOI: 10.1292/jvms.67.667]
- 23 **Komine K**, Kuroishi T, Ozawa A, Komine Y, Minami T, Shimauchi H, Sugawara S. Cleaved inflammatory lactoferrin peptides in parotid saliva of periodontitis patients. *Mol Immunol* 2007; **44**: 1498-1508 [PMID: 17030385 DOI: 10.1016/j.molimm.2006.09.003]
- 24 **Olivier AJ**, Masson L, Ronacher K, Walzl G, Coetzee D, Lewis DA, Williamson AL, Passmore JA, Burgers WA. Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation. *J Infect Dis* 2014; **209**: 1174-1184 [PMID: 24273175 DOI: 10.1093/infdis/jit649]

**P- Reviewers:** Gokul S, Louboutin JP, Shih WL, Said ZNA

**S- Editor:** Wen LL **L- Editor:** A **E- Editor:** Liu SQ





## INSTRUCTIONS TO AUTHORS

### GENERAL INFORMATION

*World Journal of Virology* (*World J Virol*, *WJV*, online ISSN 2220-3249, DOI: 10.5501) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

#### Aim and scope

*WJV* covers topics concerning arboviral infections, bronchiolitis, central nervous system viral diseases, DNA virus infections, encephalitis, eye infections, fatigue syndrome, hepatitis, meningitis, opportunistic infections, pneumonia, RNA virus infections, sexually transmitted diseases, skin diseases, slow virus diseases, tumor virus infections, viremia, zoonoses, and virology-related traditional medicine, and integrated Chinese and Western medicine. The current columns of *WJV* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of viral diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJV*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

*WJV* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 43 OA clinical medical journals, including 42 in English, has a total of 15471 editorial board members or peer reviewers, and is a world first-class publisher.

#### Columns

The columns in the issues of *WJV* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement

therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in virology; (12) Research Report: To briefly report the novel and innovative findings in virology; (13) Meta-Analysis: To evaluate the clinical effectiveness in virology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJV*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of virology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

#### Name of journal

*World Journal of Virology*

#### ISSN

ISSN 2220-3249 (online)

## Instructions to authors

### Launch date

February 12, 2012

### Frequency

Quarterly

### Editor-in-Chief

**Ling Lu, MD, PhD**, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, 3901 Rainbow Blvd, WHE 3020, KS 66160, United States

### Editorial office

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Virology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: editorialoffice@wjnet.com  
Help Desk: <http://www.wjnet.com/esps/helpdesk.aspx>  
<http://www.wjnet.com>

### Publisher

Baishideng Publishing Group Inc  
8226 Regency Drive,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: bpgoffice@wjnet.com  
Help Desk: <http://www.wjnet.com/esps/helpdesk.aspx>  
<http://www.wjnet.com>

### Instructions to authors

Full instructions are available online at [http://www.wjnet.com/2220-3249/g\\_info\\_20100722180909.htm](http://www.wjnet.com/2220-3249/g_info_20100722180909.htm).

### Indexed and Abstracted in

Digital Object Identifier.

## SPECIAL STATEMENT

All articles published in journals owned by the BPG represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJV* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular

paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of BPG, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the



contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2220-3249/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2220-3249/g_info_20100722180909.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, *e.g.*, Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, *e.g.*, Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, *e.g.*,  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* <

## Instructions to authors

0.05, <sup>b</sup> $P < 0.01$  should be noted ( $P > 0.05$  should not be noted). If there are other series of  $P$  values, <sup>c</sup> $P < 0.05$  and <sup>d</sup> $P < 0.01$  are used. A third series of  $P$  values can be expressed as <sup>e</sup> $P < 0.05$  and <sup>f</sup> $P < 0.01$ . Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g., PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature

of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.



**Statistical expression**

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *ν* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Units**

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6  $24.5 \mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: [http://www.wjgnet.com/2220-3249/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2220-3249/g_info_20100725073806.htm).

**Abbreviations**

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

**Italics**

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kbo I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

**Examples for paper writing**

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

**RESUBMISSION OF THE REVISED MANUSCRIPTS**

Authors must revise their manuscript carefully according to the revision policies of BPG. The revised version, along with the

signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

**Language evaluation**

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

**Copyright assignment form**

Please download a Copyright assignment form from [http://www.wjgnet.com/2220-3249/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2220-3249/g_info_20100725073726.htm).

**Responses to reviewers**

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2220-3249/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2220-3249/g_info_20100725073445.htm).

**Proof of financial support**

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

**STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS**

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

**PUBLICATION FEE**

*WJV* is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 698 USD per article. All invited articles are published free of charge.



Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

